There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
Sciences Inc.’s shares plunged Friday after the drugmaker said a promising hepatitis C treatment it acquired as part of the $11 billion Pharmasset purchase may need help from other drugs to effectively treat some patients. The Foster City, Calif. ,...
Photographer: Alexander Zemlianichenko Jr/Bloomberg Feb. 20 (Bloomberg) -- Peter Garnry, an equity strategist at Saxo Bank A/S, discusses the Greek debt crisis and his recommendation of Apple Inc. , Microsoft Corp. , AstraZeneca Plc and Gilead Sciences...
COMMERCIAL IMAGE - In this photograph was taken by AP Images for AIDS Healthcare Foundation, AIDS protestors carries signs with the picture of John C. Martin, CEO of Gilead Sciences Inc. to protest the company's pricing of its HIV/AIDS medications... View Photo »
He speaks from Tokyo with Susan Li on Bloomberg Television's "First Up." (Source: Bloomberg) Feb. 20 (Bloomberg) -- Peter Garnry, an equity strategist at Saxo Bank A/S, discusses the Greek debt crisis and his recommendation of Apple Inc. , Microsoft...
Sciences said a promising hepatitis C treatment it recently acquired may have to be used with other drugs. For more from BostonGlobe.com, sign up or log in below Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com...
Kepler / Bloomberg A former executive of SanDisk, which makes memory cards, has entered into a plea agreement. PHARMACEUTICAL Gilead slides on trial result Gilead Sciences, which fueled a rush for hepatitis C therapies with its $10.8 billion purchase...
COMMERCIAL IMAGE - In this photograph taken by AP Images for AIDS Healthcare Foundation, AIDS protestors are seen outside the Gilead Sciences Inc. headquarters to protest the company's pricing of its HIV/AIDS medications on Wednesday, Nov. 30, 2011, in... View Photo »
Pharmaceuticals’ new headquarters rises along Fan Pier. (David L Ryan/Globe Staff Photo/File) Gilead Sciences Inc. plunged after some patients on an experimental hepatitis C medicine relapsed after they stopped therapy. For more from BostonGlobe.com,...
"If it works in a few patients, it should work in a larger trial" is a reasonable hypothesis, but it's not a fact. Apparently overreacting to negative news from a small trial is possible too, especially for a company like Gilead Sciences (Nasdaq: GILD...
Gilead Sciences (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B or influenza. In 2006, Gilead acquired two companies that were developing... Full Article
COMMERCIAL IMAGE - In this photograph taken by AP Images for AIDS Healthcare Foundation, AIDS protestors are seen outside the Gilead Sciences Inc. headquarters to protest the company's pricing of its HIV/AIDS medications on Wednesday, Nov. 30, 2011, in Foster City, Calif. AIDS advocates...
View Photo »COMMERCIAL IMAGE - In this photo taken by AP Images for AIDS Healthcare Foundation, supporters of the AIDS Healthcare Foundation protest for reduced HIV drug pricing at Gilead Sciences in Foster City, Calif. , on Wednesday, Sept. 14, 2011. The protestors dressed in mourning for those...
View Photo »Tomorrow, AIDS activists plan to stage a third "die-in" protest outside the headquarters of Gilead Sciences Inc. to protest the company's pricing of its HIV/AIDS medications.
View Photo »Joseph Terrill, AIDS advocate and Domestic Advocacy Manager for AIDS Healthcare Foundation, delivers two large mail bags stuffed with 1,593 letters address to Gilead Sciences Inc.'s CEO John Martin at the company's headquarters in Foster City, CA criticizing Gilead's irresponsible AIDS drug...
View Photo »COMMERCIAL IMAGE - In this photograph taken by AP Images for AIDS Healthcare Foundation, Protesters from the AIDS Healthcare Foundation participate in a "Die-in" and protest at Gilead Sciences to protest the company's pricing of its HIV/AIDS medications outside the Gilead Sciences Inc. headquarters...
View Photo »COMMERCIAL IMAGE - In this photograph taken by AP Images for AIDS Healthcare Foundation, Joey Terrill, right, domestic advocacy manager for AIDS Healthcare Foundation, delivers bags of support letters to a Gilead employee for John C. Martin, CEO of Gilead Sciences Inc. to protest the company's...
View Photo »COMMERCIAL IMAGE - In this photo taken by AP Images for AIDS Healthcare Foundation, Adam Ouderkirk, from San Francisco, lays on the ground outside the Gilead Sciences Inc. headquarters to protest the company's pricing of its HIV/AIDS medications on Wednesday, Aug. 3, 2011, in Foster...
View Photo »A group of committed AIDS activists and advocates spearheaded by AIDS Healthcare Foundation (AHF) protested Gilead Sciences outside its Foster City headquarters earlier today over Gilead's pricing and policies on its HIV/AIDS medications.
View Photo »COMMERCIAL IMAGE - In this photograph taken by AP Images for AIDS Healthcare Foundation, AIDS protestors are seen outside the Gilead Sciences Inc. headquarters to protest the company's pricing of its HIV/AIDS medications on Wednesday, Nov. 30, 2011, in Foster City, Calif. AIDS advocates...
View Photo »There are no results for this module. Edit the module to change the search term used to query related quotes.
We found no quotes related to Gilead Sciences, Inc..
